|
Afatinib in the treatment of EGFR mutation-positive NSCLC — a network meta-analysis |
Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L |
|
|
Record Status This is a systematic review that meets the criteria for inclusion on DARE. Bibliographic details Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L. Afatinib in the treatment of EGFR mutation-positive NSCLC — a network meta-analysis. Lung Cancer 2014; 85(2): 230-238 Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /genetics /mortality /pathology; Humans; Lung Neoplasms /drug therapy /genetics /mortality /pathology; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors /therapeutic use; Quinazolines /therapeutic use; Receptor, Epidermal Growth Factor /genetics; Treatment Outcome AccessionNumber 12014039324 Date bibliographic record published 24/09/2014 |
|
|
|